Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jason Otto

Physician Assistant, Medical Sheridan, WY Physician Assistant

NPI 1558697177 CMS profile 10656143

1333 W 5Th St Ste 112, Sheridan, WY 82801

Open in the dashboard

General payments

$607

32 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Otto of Sheridan, WY is reported in the CMS Open Payments database as having received $607 across 32 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $146 6
2024 General $122 6
2023 General $143 9
2022 General $100 5
2021 General $96 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Otto
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jason Otto were reported at $146. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jason Otto Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $96 $156 $41–$563 $132
2022 $100 $185 $55–$649 $149
2023 $143 $199 $58–$717 $160
2024 $122 $206 $62–$740 $164
2025 $146 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $204 12 payments
  2. Insmed, Inc. $106 4 payments
  3. Abbott Laboratories $60 3 payments
  4. Novo Nordisk Inc $54 3 payments
  5. Inspire Medical Systems, Inc. $37 1 payment
  6. Novartis Pharmaceuticals Corporation $32 2 payments
  7. E.R. Squibb & Sons, L.L.C. $28 2 payments
  8. Astellas Pharma US Inc $27 1 payment
  9. Janssen Pharmaceuticals, Inc $19 1 payment
  10. Lilly USA, LLC $15 1 payment
  11. Other $26 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $607 32 payments
Products named General payments · program years 2021–2025
  1. SHINGRIX $112 7 payments
  2. TRELEGY ELLIPTA $106 6 payments
  3. Arikayce $106 4 payments
  4. AREXVY $81 5 payments
  5. RYBELSUS $54 3 payments
  6. Ozempic $54 3 payments
  7. FREESTYLE LIBRE $45 2 payments
  8. INSPIRE $37 1 payment
  9. ELIQUIS $28 2 payments
  10. Veozah $27 1 payment
  11. Other $201 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 139 drugs

Part D claims

9,003

Median for Physician Assistant: 241

Drug cost

$900,208

Median for Physician Assistant: $4,110

Branded share of claims

20.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 251 $198,799
Jardiance Empagliflozin Brand 83 $79,836
Xarelto Rivaroxaban Brand 58 $60,050
Ozempic Semaglutide Brand 48 $53,460
Januvia Sitagliptin Phosphate Brand 39 $48,191
Trulicity Dulaglutide Brand 40 $47,613
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 28 $35,024
Tresiba Flextouch U-100 Insulin Degludec Brand 47 $24,407
Farxiga Dapagliflozin Propanediol Brand 23 $24,128
Mounjaro Tirzepatide Brand 23 $22,829

The 10 drugs with the highest cost, of 139 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$168,668

Of which drugs: $46,166

Medicare patients

643

Average age 76

Services billed

2,432

300 women, 343 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 30%
Diabetes 26%
Ischemic heart disease 23%
Atrial fibrillation 22%
COPD 15%
Heart failure 14%
Depression 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 124 124 $35,997
Vaccine for influenza for injection into muscle 90662 Office 68 68 $5,564

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTRESTO
  • Novartis Pharmaceuticals Corporation $17
$17 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $15
$15 251 —
RYBELSUS
  • Novo Nordisk Inc $12
$12 — —
Ozempic
  • Novo Nordisk Inc $12
$12 48 —
MOUNJARO
  • Lilly USA, LLC $8
$8 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

32 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Wyoming

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record